Advanced Metastatic Non Small Cell Lung Cancer clinical trials

Explore recruiting advanced metastatic non small cell lung cancer clinical trials.

Recruiting advanced metastatic non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Metastatic Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL 1L)

Netherlands, Poland, Hungary, Romania, Germany, Bulgaria +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.

France, Italy, Greece, Poland, Spain, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

France, Denmark, Poland, Italy, Belgium, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.

Romania, Lithuania, Bulgaria, Latvia, Greece, Spain +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-agent Chemotherapy as Third-line Treatment in Subjects with Advanced / Metastatic Non-Small Cell Lung Cancer (NSCLC)

Poland, Hungary, Romania, Spain, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

EXL-01 in combination with nivolumab for advanced NSCLC refractory to immunotherapy'

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Advanced Metastatic Non Small Cell Lung Cancer trials by city

Advanced Metastatic Non Small Cell Lung Cancer in Toronto Advanced Metastatic Non Small Cell Lung Cancer in Vancouver Advanced Metastatic Non Small Cell Lung Cancer in Montreal Advanced Metastatic Non Small Cell Lung Cancer in Calgary Advanced Metastatic Non Small Cell Lung Cancer in Edmonton Advanced Metastatic Non Small Cell Lung Cancer in Ottawa Advanced Metastatic Non Small Cell Lung Cancer in Winnipeg Advanced Metastatic Non Small Cell Lung Cancer in Quebec City Advanced Metastatic Non Small Cell Lung Cancer in Hamilton Advanced Metastatic Non Small Cell Lung Cancer in Kitchener Advanced Metastatic Non Small Cell Lung Cancer in London Advanced Metastatic Non Small Cell Lung Cancer in Halifax Advanced Metastatic Non Small Cell Lung Cancer in New York Advanced Metastatic Non Small Cell Lung Cancer in Los Angeles Advanced Metastatic Non Small Cell Lung Cancer in Chicago Advanced Metastatic Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease